Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
BUSINESS
Haihe Steps into Japan Oncology Space as CEO Sees Growth Potential
China-based Haihe Biopharma introduced its first product in Japan last fall, making a foray into the country’s oncology market with the lung cancer drug Haiyitan (gumarontinib). CEO Ruiping Dong shared the plans and strategies of his company in a recent…
To read the full story
Related Article
- Haihe’s MET Inhibitor Haiyitan Set for Launch on Oct. 11
September 25, 2024
- Novartis’ Fabhalta, UCB’s Briviact and More to Join NHI Price List on Aug. 15
August 8, 2024
- Taiho Picks Up Rights to China Pharma’s Lung Cancer Drug
March 4, 2024
BUSINESS
- Santen’s Glaucoma Drug Tapcom Snags China Approval
April 7, 2025
- Sanofi Launches Epidemiological Study for Beyfortus in Japan
April 7, 2025
- Struggling Sumitomo Extends Pay Cuts for Board Directors
April 7, 2025
- Japan Generic Use Rate Vaults to 88.6% in October-December: JGA
April 7, 2025
- Enhertu Approved for HER2-Low/Ultralow Breast Cancer in Europe
April 7, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…